Equities

Pliant Therapeutics Inc

Pliant Therapeutics Inc

Actions
  • Price (USD)12.98
  • Today's Change0.13 / 1.01%
  • Shares traded586.02k
  • 1 Year change-6.82%
  • Beta1.0620
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy4
Outperform9
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 10 analysts offering 12 month price targets for Pliant Therapeutics Inc have a median target of 40.00, with a high estimate of 45.00 and a low estimate of 32.00. The median estimate represents a 211.28% increase from the last price of 12.85.
High250.2%45.00
Med211.3%40.00
Low149.0%32.00

Earnings history & estimates in USD

On Nov 07, 2024, Pliant Therapeutics Inc reported 3rd quarter 2024 losses of -0.95 per share. This result was in line with the consensus of the 12 analysts following the company and under-performed last year's 3rd quarter results by 35.71%.
The next earnings announcement is expected on Feb 25, 2025.
Average growth rate-8.21%
Pliant Therapeutics Inc reported annual 2023 losses of -2.75 per share on Feb 27, 2024.
Average growth rate-13.68%
More ▼

Revenue history & estimates in USD

Pliant Therapeutics, Inc. did not report revenues for the 3rd quarter 2024. However, during the 3rd quarter of the prior year the company reported revenues of 1.33m.
Average growth rate0.00%
Pliant Therapeutics, Inc. had revenues for the full year 2023 of 1.58m. This was 83.69% below the prior year's results.
Average growth rate-45.89%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.